Nina Hibbard
Family · Daphne, ALNPI 1568800712
Payments from drug & device makers
Across 534 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Tandem Diabetes Care, Inc.$2K
- Lilly USA, LLC$2K
- Bayer$1K
- Medtronic$832
- Dexcom, Inc.$546
- plus $3K from 29 others
What the payments were for
- Consulting fees$1,1409%
- Travel & lodging$1,92116%
- Food & beverage$8,95274%
- Education$831%
- Other$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 124 | $2,528 |
| Tandem Diabetes Care, Inc. | 19 | $2,009 |
| Lilly USA, LLC | 79 | $1,587 |
| Bayer | 80 | $1,304 |
| Medtronic | 12 | $832 |
| Dexcom, Inc. | 36 | $546 |
| Xeris Pharmaceuticals, Inc. | 20 | $414 |
| Abbott | 23 | $349 |
| Boehringer Ingelheim | 16 | $266 |
| Corcept Therapeutics | 13 | $252 |
| AstraZeneca | 15 | $247 |
| Insulet Corporation | 10 | $239 |
| Sanofi-aventis U.S. LLC | 13 | $235 |
| Amgen | 14 | $228 |
| AbbVie | 9 | $179 |
| Radius Health, Inc. | 8 | $144 |
| Novartis | 6 | $114 |
| Averitas Pharma Inc. | 5 | $87 |
| Amneal Pharmaceuticals LLC | 5 | $71 |
| Recordati_rare_diseases_inc. | 3 | $65 |
| Amarin Pharma, Inc. | 3 | $55 |
| IBSA Pharma Inc. | 3 | $50 |
| Mannkind Corporation | 3 | $46 |
| Tolmar, Inc. | 2 | $32 |
| Chiesi USA, Inc. | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| Rhythm Pharmaceuticals, Inc. | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| GSK | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $15 |
| OPKO Pharmaceuticals, LLC | 1 | $14 |
| Cequr Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 Insulin Pump with Control-IQ$1,711
- RYBELSUS$1,140
- MINIMED 780G$646
- Kerendia$250
- Ozempic$122
- DEXCOM G7 GSS (161)$113
- DEXCOM STELO GLUCOSE BIOSENSOR$113
How this compares
$12,116 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 516 | $650,555 |
| OzempicSemaglutide | 267 | $385,389 |
| Tresiba Flextouch U-200Insulin Degludec | 227 | $260,898 |
| JardianceEmpagliflozin | 101 | $136,818 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 115 | $133,497 |
| FarxigaDapagliflozin Propanediol | 129 | $128,873 |
| KerendiaFinerenone | 89 | $95,485 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $87,963 |
| TrulicityDulaglutide | 39 | $41,805 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $40,218 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $38,798 |
| Humalog Kwikpen U-100Insulin Lispro | 139 | $38,461 |
| Tresiba Flextouch U-100Insulin Degludec | 69 | $35,221 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 37 | $30,042 |
| VascepaIcosapent Ethyl | 35 | $23,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,587 | $715,830636 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $2,528 | $414,750311 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $266 | $166,860138 claims |
| AstraZenecaFarxiga | $247 | $128,873129 claims |
| BayerKerendia | $1,304 | $95,48589 claims |
| AbbVieSynthroid | $179 | $5,84053 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $71 | $1,839199 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Daphne
- Daniel GardnerDaphne$13K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.